Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors
Franck E. Nicolini,
H. Jean Khoury,
Luke Akard,
Delphine Rea,
Hagop Kantarjian,
Michele Baccarani,
Janis Leonoudakis,
Adam Craig,
Annie-Claude Benichou,
Jorge Cortes
Affiliations
Franck E. Nicolini
Hematology department 1G, Centre Hospitalier Lyon Sud, Pierre Bénite, France
H. Jean Khoury
Emory University School of Medicine, Atlanta, Georgia, USA
Luke Akard
Indiana Blood and Marrow Transplantation at St. Francis Health, Indianapolis, Indiana, USA
Delphine Rea
Service des Maladies du Sang, EA3518 and CIC, Hôpital Saint-Louis, Paris, France
Hagop Kantarjian
University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Michele Baccarani
University of Bologna, Bologna, Italy
Janis Leonoudakis
Powered 4 Significance LLC, Bloomsbury, New Jersey, USA
Adam Craig
formerly of ChemGenex Pharmaceuticals, an indirect wholly owned subsidiary of Teva Pharmaceutical Industries Ltd., Petach Tikva, Israel
Annie-Claude Benichou
formerly of ChemGenex Pharmaceuticals, an indirect wholly owned subsidiary of Teva Pharmaceutical Industries Ltd., Petach Tikva, Israel
Jorge Cortes
University of Texas MD Anderson Cancer Center, Houston, Texas, USA